{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:18:21Z","timestamp":1777619901025,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We retrospectively compared the outcomes of 166 patients with hematological malignancies who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) using ATG-Thymoglobulin (ATG-T) at 10\u00a0mg\/kg or ATG-Fresenius (ATG-F) at 20\u00a0mg\/kg. Propensity score matching (PSM) analysis was applied, with 44 patients assigned to each group. The ATG-T group showed a trend toward a higher incidence of bacterial infections (72.7% vs. 65.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.064). Additionally, the ATG-T group had a significantly higher incidence of other viral infections, including BK virus and herpes zoster virus (40.9% vs. 15.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.003), compared to the ATG-F group. Furthermore, the ATG-F group experienced a lower incidence of high fever (4.5% vs. 50.0%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and reduced ATG treatment costs [\u00a5 45100 (28700\u201382000) vs. \u00a5 56250 (38000\u201385000), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001] compared to ATG-T. The incidences of acute GVHD, grade III-IV aGVHD, grades of aGVHD, chronic GVHD, 3-year overall survival (OS), transplantation-related mortality (TRM), non-relapse mortality (NRM), disease-free survival (DFS), and GVHD-free and relapse-free survival (GRFS) were similar between the ATG-T and ATG-F groups. In conclusion, our study suggests that ATG-F is superior to ATG-T in terms of viral infections, fever rate, and treatment cost.<\/jats:p>","DOI":"10.1007\/s00277-025-06267-4","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:43:00Z","timestamp":1740710580000},"page":"1907-1916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Hanyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"6267_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12703\/r\/12-4","volume":"12","author":"AM Flinn","year":"2023","unstructured":"Flinn AM, Gennery AR (2023) Recent advances in graft-versus-host disease. Fac Rev 12:4","journal-title":"Fac Rev"},{"key":"6267_CR2","doi-asserted-by":"crossref","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","volume":"12","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Antin JH (2021) GVHD Prophylaxis 2020. Front Immunol 12:605726","journal-title":"Front Immunol"},{"issue":"1","key":"6267_CR3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/hematology.2023000427","volume":"2023","author":"I Amanam","year":"2023","unstructured":"Amanam I, Otoukesh S, Al Malki MM et al (2023) Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematol Am Soc Hematol Educ Program 2023(1):164\u2013170","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"6267_CR4","first-page":"1","volume":"37","author":"E Alada\u011f","year":"2020","unstructured":"Alada\u011f E, Kelkitli E, G\u00f6ker H (2020) Acute graft-versus-host disease: a brief review. Turk J Haematol 37(1):1\u20134","journal-title":"Turk J Haematol"},{"issue":"1","key":"6267_CR5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12962-023-00444-w","volume":"21","author":"JCM Ong","year":"2023","unstructured":"Ong JCM, Than H, Tripathi S et al (2023) A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged\u2009>\u200912 years in Singapore. Cost Eff Resour Alloc 21(1):34","journal-title":"Cost Eff Resour Alloc"},{"issue":"26","key":"6267_CR6","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579","journal-title":"N Engl J Med"},{"issue":"8","key":"6267_CR7","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"DP Lu","year":"2006","unstructured":"Lu DP, Dong L, Wu T et al (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065\u20133073","journal-title":"Blood"},{"issue":"5","key":"6267_CR8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","volume":"12","author":"A Bacigalupo","year":"2006","unstructured":"Bacigalupo A, Lamparelli T, Barisione G et al (2006) Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transpl 12(5):560\u2013565","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"6267_CR9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855\u2013864","journal-title":"Lancet Oncol"},{"issue":"23","key":"6267_CR10","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","volume":"117","author":"G Soci\u00e9","year":"2011","unstructured":"Soci\u00e9 G, Schmoor C, Bethge WA et al (2011) Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 117(23):6375\u20136382","journal-title":"Blood"},{"issue":"6","key":"6267_CR11","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA et al (2017) Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-t-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol 4(6):e293\u2013e301","journal-title":"Lancet Haematol"},{"issue":"10","key":"6267_CR12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/bmt.2017.153","volume":"52","author":"K Kawamura","year":"2017","unstructured":"Kawamura K, Kanda J, Fuji S et al (2017) Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation. Bone Marrow Transpl 52(10):1390\u20131398","journal-title":"Bone Marrow Transpl"},{"issue":"36","key":"6267_CR13","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer RJ, Kim HT, McGuirk J et al (2017) Randomized, Double-Blind, phase III clinical trial of Anti-T-Lymphocyte Globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-Matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol 35(36):4003\u20134011Prospective","journal-title":"J Clin Oncol"},{"issue":"1","key":"6267_CR14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-016-0295-9","volume":"9","author":"MT Rubio","year":"2016","unstructured":"Rubio MT, Savani BN, Labopin M et al (2016) The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. J Hematol Oncol 9(1):65","journal-title":"J Hematol Oncol"},{"issue":"7","key":"6267_CR15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41409-018-0393-0","volume":"54","author":"A Kumar","year":"2019","unstructured":"Kumar A, Reljic T, Hamadani M et al (2019) Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transpl 54(7):1094\u20131106","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"6267_CR16","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P et al (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98(10):2942\u20132947","journal-title":"Blood"},{"issue":"2","key":"6267_CR17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker I, Panzarella T, Couban S et al (2016) Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17(2):164\u2013173","journal-title":"Lancet Oncol"},{"issue":"11","key":"6267_CR18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/01.TP.0000164159.20075.16","volume":"79","author":"MS Zand","year":"2005","unstructured":"Zand MS, Vo T, Huggins J et al (2005) Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79(11):1507\u20131515","journal-title":"Transplantation"},{"issue":"7","key":"6267_CR19","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2005-06-2269","volume":"107","author":"MS Zand","year":"2006","unstructured":"Zand MS, Vo T, Pellegrin T et al (2006) Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 107(7):2895\u20132903","journal-title":"Blood"},{"issue":"3","key":"6267_CR20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.transproceed.2017.02.005","volume":"49","author":"M Yilmaz","year":"2017","unstructured":"Yilmaz M, Sezer T\u00d6, G\u00fcnay E et al (2017) Efficacy and safety of ATG-Fresenius as an induction Agent in Living-Donor kidney transplantation. Transpl Proc 49(3):481\u2013485","journal-title":"Transpl Proc"},{"key":"6267_CR21","doi-asserted-by":"crossref","first-page":"1045580","DOI":"10.3389\/fimmu.2022.1045580","volume":"13","author":"M Sebti","year":"2022","unstructured":"Sebti M, Petit-Hoang C, Chami B et al (2022) ATG-Fresenius increases the risk of red blood cell transfusion after kidney transplantation. Front Immunol 13:1045580","journal-title":"Front Immunol"},{"key":"6267_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fimmu.2020.00457","volume":"11","author":"T Song","year":"2020","unstructured":"Song T, Yin S, Li X et al (2020) Thymoglobulin vs. ATG-Fresenius as induction therapy in kidney transplantation: a bayesian network Meta-analysis of Randomized controlled trials. Front Immunol 11:457","journal-title":"Front Immunol"},{"issue":"4","key":"6267_CR23","first-page":"1355","volume":"29","author":"F Ayuk","year":"2009","unstructured":"Ayuk F, Maywald N, Hannemann S et al (2009) Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. Anticancer Res 29(4):1355\u20131360","journal-title":"Anticancer Res"},{"issue":"8","key":"6267_CR24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1701991","volume":"24","author":"M Remberger","year":"1999","unstructured":"Remberger M, Svahn BM, Hentschke P et al (1999) Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transpl 24(8):823\u2013830","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"6267_CR25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bmt.1704957","volume":"35","author":"N Basara","year":"2005","unstructured":"Basara N, Baurmann H, Kolbe K et al (2005) Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transpl 35(10):1011\u20131018","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6267_CR26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/10428194.2015.1045901","volume":"57","author":"W Huang","year":"2016","unstructured":"Huang W, Yu L, Cao T et al (2016) The efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors. Leuk Lymphoma 57(2):355\u2013363","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6267_CR27","first-page":"465","volume":"32","author":"W Huang","year":"2015","unstructured":"Huang W, Zhao X, Tian Y et al (2015) Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study. Med Oncol 32(2):465","journal-title":"Med Oncol"},{"issue":"11","key":"6267_CR28","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1080\/10428194.2018.1439584","volume":"59","author":"N Polverelli","year":"2018","unstructured":"Polverelli N, Malagola M, Turra A et al (2018) Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years. Leuk Lymphoma 59(11):2700\u20132705","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6267_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46701\/BG.2023012022036","volume":"7","author":"P Zhu","year":"2023","unstructured":"Zhu P, Wu Y, Luo Y (2023) ABO-incompatible allogeneic hematopoietic stem cell transplantation. Blood&Genomics 7(1):1\u201312","journal-title":"Blood&Genomics"},{"key":"6267_CR30","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant.;15(6):825-8"},{"issue":"3","key":"6267_CR31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National Institutes of Health Consensus Development Project on Criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and Staging Working Group report. Biol Blood Marrow Transpl 21(3):389\u2013401e1 Epub 2014 Dec 18","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"6267_CR32","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","volume":"110","author":"S Bhatia","year":"2007","unstructured":"Bhatia S, Francisco L, Carter A et al (2007) Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the bone marrow transplant Survivor Study. Blood 110(10):3784\u20133792","journal-title":"Blood"},{"issue":"12","key":"6267_CR33","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2012-11-465583","volume":"121","author":"Y Inamoto","year":"2013","unstructured":"Inamoto Y, Storer BE, Lee SJ et al (2013) Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood 121(12):2340\u20132346","journal-title":"Blood"},{"key":"6267_CR34","doi-asserted-by":"crossref","first-page":"102944","DOI":"10.1016\/j.critrevonc.2020.102944","volume":"150","author":"X Lv","year":"2020","unstructured":"Lv X, Qi J, Zhou M, Shi B et al (2020) Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: a multiple-treatments network meta-analysis. Crit Rev Oncol Hematol 150:102944","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"6267_CR35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2023020073","volume":"142","author":"O Jamy","year":"2023","unstructured":"Jamy O, Zeiser R, Chen YB (2023) Novel developments in the prophylaxis and treatment of acute GVHD. Blood 142(12):1037\u20131046","journal-title":"Blood"},{"issue":"2","key":"6267_CR36","first-page":"137","volume":"6","author":"M Mrsi\u0107","year":"1990","unstructured":"Mrsi\u0107 M, Labar B, Bogdani\u0107 V et al (1990) Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transpl 6(2):137\u2013141","journal-title":"Bone Marrow Transpl"},{"key":"6267_CR37","doi-asserted-by":"publisher","unstructured":"Rezvani AR, Storb RF (2012) Prevention of graft-vs.-host disease. Expert Opin Pharmacother.;13(12):1737-50. https:\/\/doi.org\/10.1517\/14656566.2012.703652IF: 2.5 Q3. Epub 2012 Jul 7","DOI":"10.1517\/14656566.2012.703652IF"},{"issue":"4","key":"6267_CR38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2020.271445","volume":"107","author":"R Massoud","year":"2022","unstructured":"Massoud R, Gagelmann N, Fritzsche-Friedland U et al (2022) Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica 107(4):857\u2013867","journal-title":"Haematologica"},{"issue":"16","key":"6267_CR39","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1200\/JCO.2001.19.16.3685","volume":"19","author":"C Cutler","year":"2001","unstructured":"Cutler C, Giri S, Jeyapalan S et al (2001) Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19(16):3685\u20133691","journal-title":"J Clin Oncol"},{"issue":"13","key":"6267_CR40","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1182\/blood-2006-05-024042","volume":"108","author":"N Schmitz","year":"2006","unstructured":"Schmitz N, Eapen M, Horowitz MM et al (2006) Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for blood and marrow transplantation. Blood 108(13):4288\u20134290","journal-title":"Blood"},{"issue":"12","key":"6267_CR41","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood.V90.12.4705","volume":"90","author":"J Storek","year":"1997","unstructured":"Storek J, Gooley T, Siadak M et al (1997) Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90(12):4705\u20134709","journal-title":"Blood"},{"issue":"25","key":"6267_CR42","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","volume":"117","author":"RJ Soiffer","year":"2011","unstructured":"Soiffer RJ, Lerademacher J, Ho V et al (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117(25):6963\u20136970. https:\/\/doi.org\/10.1182\/blood-2011-01-332007Epub 2011 Apr 4","journal-title":"Blood"},{"issue":"2","key":"6267_CR43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2016.148510","volume":"102","author":"F Baron","year":"2017","unstructured":"Baron F, Mohty M, Blaise D et al (2017) Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and marrow transplantation. Haematologica 102(2):224\u2013234","journal-title":"Haematologica"},{"issue":"11","key":"6267_CR44","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.tp.0000244063.05338.27","volume":"82","author":"MS Zand","year":"2006","unstructured":"Zand MS (2006) B-cell activity of polyclonal antithymocyte globulins. Transplantation 82(11):1387\u20131395","journal-title":"Transplantation"},{"issue":"7","key":"6267_CR45","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","volume":"21","author":"M Mohty","year":"2007","unstructured":"Mohty M (2007) Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21(7):1387\u20131394","journal-title":"Leukemia"},{"issue":"2","key":"6267_CR46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trim.2007.05.001","volume":"18","author":"O Penack","year":"2007","unstructured":"Penack O, Fischer L, Gentilini C et al (2007) The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 18(2):85\u201387","journal-title":"Transpl Immunol"},{"issue":"12","key":"6267_CR47","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/ajt.12514","volume":"13","author":"I Popow","year":"2013","unstructured":"Popow I, Leitner J, Grabmeier-Pfistershammer K et al (2013) A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transpl 13(12):3103\u20133113","journal-title":"Am J Transpl"},{"issue":"12","key":"6267_CR48","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.bbmt.2017.08.027","volume":"23","author":"N Gagelmann","year":"2017","unstructured":"Gagelmann N, Ayuk F, Wolschke C et al (2017) Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network Meta-analysis. Biol Blood Marrow Transpl 23(12):2184\u20132191","journal-title":"Biol Blood Marrow Transpl"},{"key":"6267_CR49","doi-asserted-by":"crossref","first-page":"980924","DOI":"10.1155\/2015\/980924","volume":"2015","author":"S Paiano","year":"2015","unstructured":"Paiano S, Roosnek E, Tirefort Y et al (2015) Comparing two types of rabbit ATG prior to reduced intensity conditioning allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Res 2015:980924","journal-title":"Bone Marrow Res"},{"issue":"6","key":"6267_CR50","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00277-023-05220-7","volume":"102","author":"L Wang","year":"2023","unstructured":"Wang L, Kong P, Zhang C et al (2023) Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme. Ann Hematol 102(6):1569\u20131579","journal-title":"Ann Hematol"},{"issue":"6","key":"6267_CR51","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-020-04014-5","volume":"99","author":"L Zhou","year":"2020","unstructured":"Zhou L, Gao ZY, Lu DP (2020) Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience. Ann Hematol 99(6):1389\u20131400","journal-title":"Ann Hematol"},{"issue":"10","key":"6267_CR52","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/s41409-022-01666-x","volume":"57","author":"R Massoud","year":"2022","unstructured":"Massoud R, Klyuchnikov E, Gagelmann N et al (2022) Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transpl 57(10):1548\u20131555","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"6267_CR53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","volume":"49","author":"Y Wang","year":"2014","unstructured":"Wang Y, Fu HX, Liu DH et al (2014) Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transpl 49(3):426\u2013433","journal-title":"Bone Marrow Transpl"},{"issue":"15","key":"6267_CR54","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","volume":"123","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Mo XD et al (2017) Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial. Cancer 123(15):2881\u20132892","journal-title":"Cancer"},{"issue":"4","key":"6267_CR55","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"R Devillier","year":"2018","unstructured":"Devillier R, Labopin M, Chevallier P et al (2018) Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of bone marrow transplantation. Bone Marrow Transpl 53(4):431\u2013437","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6267_CR56","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2008.05.023","volume":"14","author":"F Ayuk","year":"2008","unstructured":"Ayuk F, Diyachenko G, Zabelina T et al (2008) Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transpl 14(8):913\u2013919","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"6267_CR57","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(17)30417-5","volume":"18","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Bernardo ME, Bertaina A et al (2017) Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18(8):1126\u20131136","journal-title":"Lancet Oncol"},{"key":"6267_CR58","doi-asserted-by":"crossref","first-page":"732826","DOI":"10.3389\/fimmu.2021.732826","volume":"12","author":"XH Luo","year":"2021","unstructured":"Luo XH, Zhu Y, Chen YT et al (2021) CMV infection and CMV-Specific Immune reconstitution following haploidentical stem cell transplantation: an update. Front Immunol 12:732826","journal-title":"Front Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06267-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:11:05Z","timestamp":1745575865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06267-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6267"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06267-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}